Blood markers flagged lung cancer risk up to 10 years before diagnosis in a Hawaii study
University of Hawaiʻi researchers found 31 small RNA molecules in stored blood samples that were linked to lung cancer up to a decade before diagnosis. The study covered 202 smokers and still needs testing in other groups.
By Diego Callegari, Editor
· United States · 3 min read
Source: University of Hawaiʻi John A. Burns School of Medicine ↗
A set of 31 small RNA molecules carried in the blood was linked to lung cancer as much as 10 years before the disease was diagnosed, according to the University of Hawaiʻi John A. Burns School of Medicine. A computer model built on those markers sorted future patients from people who stayed cancer-free with 95% overall accuracy in testing. The study was published in Advanced Science in August.
The research used blood that had been drawn and frozen years earlier, long before anyone was diagnosed. That makes it a risk study, not a test that is ready for doctors to use.
Blood drawn from 202 smokers years before any diagnosis
The samples came from the Multiethnic Cohort Study, a long-running population study whose principal investigator, Loïc Le Marchand, works at the University of Hawaiʻi Cancer Center and co-led the paper. According to the paper in Advanced Science, the team analyzed plasma from 202 smokers, 68 of whom went on to develop lung cancer during up to 16 years of follow-up.
The researchers looked at small non-coding RNAs packed inside exosomes, tiny bubbles that cells release into the bloodstream. The final panel contains 15 microRNAs, eight PIWI-interacting RNAs, seven tRNA-derived fragments and one tRNA half. A random forest model, a common machine learning method, used the panel to reach 93% sensitivity and 100% specificity on held-out data.
The risk score stayed strongly linked to later lung cancer after the team adjusted for age, sex, ethnicity, and how much and how long people had smoked. The link was still visible in the five to 10 years before diagnosis, the school said.
“A central question in this study was whether a molecular signal of future lung cancer could already be present in blood many years before diagnosis.” — Zhuokun Feng, first author, University of Hawaiʻi
Senior author Youping Deng said the aim was "not simply to distinguish patients with established lung cancer from cancer-free individuals, but to identify molecular signals that may indicate high lung cancer risk years before clinical diagnosis."
Current screening reaches only part of the people at risk
Lung cancer is the leading cause of cancer death in the United States. The American Cancer Society estimates about 229,410 new cases and 124,990 deaths in the country in 2026, roughly one in five cancer deaths.
Screening exists, but only for a narrow group. The U.S. Preventive Services Task Force recommends a yearly low-dose CT scan for adults aged 50 to 80 who have smoked at least 20 pack-years and still smoke or quit within the past 15 years. The paper says current screening "fails to identify many individuals at risk beyond heavy smokers." A blood-based risk score could, in principle, help decide who should be scanned.
Researchers are also looking at what happens in the body in the years before a tumor appears. A team at University College London recently described an "immune fog" of regulatory T cells that builds up before lung cancer and reversed it in mice.
A small group of smokers, and no outside validation yet
The study is small. All 202 participants were smokers, so the results say nothing yet about people who never smoked, and the model has not been checked in a separate cohort. The authors write that the markers "warrant further evaluation in independent pre-diagnostic cohorts."
The team, which includes second author Masaki Nasu, is seeking a patent on the biomarker panel. The National Institutes of Health funded the work. No date has been given for a clinical test.
Not medical advice. This article reports on research and health programs for general information. Results from early studies often change in larger trials. Talk to a doctor before making decisions about your own health or treatment.
Sources
- University of Hawaiʻi John A. Burns School of Medicine · jabsom.hawaii.edu
- doi.org
- cancer.org
How we choose and verify sources: editorial policy.










